Vivos Therapeutics, Inc. (VVOS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92859E2072
Vivos Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 17.44 m USD |
| Gross profit | 10.54 m USD |
| Operating income | -19.89 m USD |
| EBIT | -19.83 m USD |
| Net income | -21.17 m USD |
| Diluted EPS – continuing operations | -2.07 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
More stocks
- ZW Data Action Technologies Inc. (CNET)
- Ocean Power Technologies, Inc. (OPTT)
- NAPC Defense, Inc. (BLIS)
- MOBIVITY HOLDINGS CORP. (MFON)
- authID Inc. (AUID)
- FARMHOUSE, INC. /NV (FMHS)
- KwikClick, Inc. (KWIK)
- ADIAL PHARMACEUTICALS, INC. (ADIL)
- CAPSTONE COMPANIES, INC. (CAPC)
- VACCINEX, INC. (VCNX)
- Toppoint Holdings Inc. (TOPP)
- PRINCETON CAPITAL CORP (PIAC)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.